ATE503757T1 - Kondensierte imidazole zur krebsbehandlung - Google Patents

Kondensierte imidazole zur krebsbehandlung

Info

Publication number
ATE503757T1
ATE503757T1 AT08787222T AT08787222T ATE503757T1 AT E503757 T1 ATE503757 T1 AT E503757T1 AT 08787222 T AT08787222 T AT 08787222T AT 08787222 T AT08787222 T AT 08787222T AT E503757 T1 ATE503757 T1 AT E503757T1
Authority
AT
Austria
Prior art keywords
cancer treatment
condensed imidazoles
imidazoles
condensed
cancer
Prior art date
Application number
AT08787222T
Other languages
English (en)
Inventor
Swen Hoelder
Armin Zuelch
Thomas Baer
Thomas Maier
Astrid Zimmermann
Thomas Beckers
Volker Gekeler
Hemant Joshi
Yogesh Munot
Umesh Bhise
Sunil Chavan
Sachin Shivatare
Sarvesh Patel
Vikas Gore
Original Assignee
Bayer Schering Pharma Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from EP07118733A external-priority patent/EP2062893A1/de
Application filed by Bayer Schering Pharma Ag filed Critical Bayer Schering Pharma Ag
Application granted granted Critical
Publication of ATE503757T1 publication Critical patent/ATE503757T1/de

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
    • A61K31/454—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. pimozide, domperidone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
    • A61K31/4545—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a six-membered ring with nitrogen as a ring hetero atom, e.g. pipamperone, anabasine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/50—Pyridazines; Hydrogenated pyridazines
    • A61K31/5025—Pyridazines; Hydrogenated pyridazines ortho- or peri-condensed with heterocyclic ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/10—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a carbon chain containing aromatic rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
    • C07D417/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D498/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D498/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
    • C07D498/04—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D513/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00
    • C07D513/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00 in which the condensed system contains two hetero rings
    • C07D513/04—Ortho-condensed systems

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
AT08787222T 2007-08-14 2008-08-14 Kondensierte imidazole zur krebsbehandlung ATE503757T1 (de)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
IN1573MU2007 2007-08-14
EP07118733A EP2062893A1 (de) 2007-10-18 2007-10-18 Fusionierte Imidazole zur Behandlung von Krebs
PCT/EP2008/060686 WO2009021990A1 (en) 2007-08-14 2008-08-14 Fused imidazoles for cancer treatment

Publications (1)

Publication Number Publication Date
ATE503757T1 true ATE503757T1 (de) 2011-04-15

Family

ID=39876840

Family Applications (1)

Application Number Title Priority Date Filing Date
AT08787222T ATE503757T1 (de) 2007-08-14 2008-08-14 Kondensierte imidazole zur krebsbehandlung

Country Status (24)

Country Link
US (2) US8592591B2 (de)
EP (1) EP2176259B1 (de)
JP (1) JP5327652B2 (de)
KR (1) KR20100049589A (de)
CN (1) CN101835776A (de)
AR (1) AR067946A1 (de)
AT (1) ATE503757T1 (de)
AU (1) AU2008288390A1 (de)
CA (1) CA2695251C (de)
CL (1) CL2008002397A1 (de)
CR (1) CR11271A (de)
DE (1) DE602008005894D1 (de)
DO (1) DOP2010000057A (de)
EA (1) EA201000297A1 (de)
EC (1) ECSP109965A (de)
MA (1) MA31609B1 (de)
MX (1) MX2010001745A (de)
PA (1) PA8793301A1 (de)
PE (1) PE20090596A1 (de)
SV (1) SV2010003482A (de)
TN (1) TN2010000071A1 (de)
TW (1) TW200924761A (de)
UY (1) UY31292A1 (de)
WO (1) WO2009021990A1 (de)

Families Citing this family (38)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7652133B2 (en) * 2006-10-19 2010-01-26 Takeda Pharmaceutical Company Limited Indole compound
US8592591B2 (en) * 2007-08-14 2013-11-26 Bayer Intellectual Property Gmbh Fused bicyclic imidazoles
WO2009046448A1 (en) 2007-10-04 2009-04-09 Intellikine, Inc. Chemical entities and therapeutic uses thereof
US7868001B2 (en) * 2007-11-02 2011-01-11 Hutchison Medipharma Enterprises Limited Cytokine inhibitors
WO2009114874A2 (en) 2008-03-14 2009-09-17 Intellikine, Inc. Benzothiazole kinase inhibitors and methods of use
JP5547099B2 (ja) 2008-03-14 2014-07-09 インテリカイン， エルエルシー キナーゼ阻害剤および使用方法
AU2009268611B2 (en) 2008-07-08 2015-04-09 Intellikine, Llc Kinase inhibitors and methods of use
US8476282B2 (en) 2008-11-03 2013-07-02 Intellikine Llc Benzoxazole kinase inhibitors and methods of use
ES2435804T3 (es) * 2009-02-13 2013-12-23 Bayer Intellectual Property Gmbh Pirimidinas condensadas como inhibidores de Akt
EP2408773A2 (de) 2009-03-20 2012-01-25 Amgen, Inc Inhibitoren von pi3-kinase
WO2010125799A1 (ja) 2009-04-27 2010-11-04 塩野義製薬株式会社 Pi3k阻害活性を有するウレア誘導体
SG178454A1 (en) 2009-08-17 2012-03-29 Intellikine Inc Heterocyclic compounds and uses thereof
EP2493889B1 (de) 2009-10-30 2017-09-06 Janssen Pharmaceutica, N.V. Imidazo[1,2-b]pyridazin-derivate und deren verwendung als pde10-inhibitoren
CN102725292A (zh) * 2009-11-02 2012-10-10 雅培制药有限公司 作为用于多靶激酶抑制的新构建物的咪唑并吡啶化合物
US9073927B2 (en) 2010-01-22 2015-07-07 Fundacion Centro Nacional De Investigaciones Oncologicas Carlos Iii Inhibitors of PI3 kinase
UY33213A (es) 2010-02-18 2011-09-30 Almirall Sa Derivados de pirazol como inhibidores de jak
AR080754A1 (es) 2010-03-09 2012-05-09 Janssen Pharmaceutica Nv Derivados de imidazo (1,2-a) pirazina y su uso como inhibidores de pde10
CA2804845A1 (en) * 2010-07-12 2012-01-19 Stuart Ince Substituted imidazo[1,2-a]pyrimidines and -pyridines
WO2012013713A2 (en) 2010-07-28 2012-02-02 Bayer Pharma Aktiengesellschaft Substituted imidazo[1,2-b]pyridazines
EP2463289A1 (de) 2010-11-26 2012-06-13 Almirall, S.A. Imidazo[1,2-b]Pyridazin-Derivate als AS JAK-Hemmer
DE102011008352A1 (de) * 2011-01-12 2012-07-12 Merck Patent Gmbh 5-([1,2,3]Triazol-4-yl)-7H-pyrrolo-[2,3-d]pyrimidinderivate
US9295673B2 (en) 2011-02-23 2016-03-29 Intellikine Llc Combination of mTOR inhibitors and P13-kinase inhibitors, and uses thereof
MY163187A (en) 2011-04-06 2017-08-15 Taiho Pharmaceutical Co Ltd Novel imidazo-oxazine compound or salt thereof
CN103596957B (zh) 2011-04-07 2016-12-07 拜耳知识产权有限责任公司 作为akt激酶抑制剂的咪唑并哒嗪
AU2012277912B2 (en) 2011-06-27 2017-03-23 Janssen Pharmaceutica Nv 1-aryl-4-methyl-[1,2,4]triazolo[4,3-a]quinoxaline derivatives
EP2554544A1 (de) 2011-08-01 2013-02-06 Almirall, S.A. Pyridin-2(1H-)-on-Derivate als JAK-Inhibitoren
CN104066735B (zh) * 2012-01-10 2016-08-31 拜耳知识产权有限责任公司 作为akt激酶抑制剂的取代的咪唑并吡嗪
US9370517B2 (en) 2012-01-10 2016-06-21 Bayer Intellectual Property Gmbh Substituted pyrazolopyrimidines as Akt kinase inhibitors
EP2863909B1 (de) 2012-06-26 2020-11-04 Janssen Pharmaceutica N.V. Kombinationen mit 4-methyl-[1,2,4]triazolo[4,3-a]chinoxalinverbindungen als pde-2-hemmern und pde-10-hemmern zur verwendung in der behandlung von neurologischen und stoffwechselerkrankungen
HUE036188T2 (hu) * 2012-07-02 2018-06-28 Taiho Pharmaceutical Co Ltd Egy imidazooxazin vegyületet tartalmazó tumorellenes hatás potenciátor
MX362197B (es) 2012-07-09 2019-01-08 Janssen Pharmaceutica Nv Derivados de imidazo[1,2-b]piridazina e imidazo[1,2-a]pirazina como inhibidores de la fosfodiesterasa 10; y el uso de los mismos en el tratamiento de trastornos neurológicos, psiquiátricos y metabólicos.
CA2907726A1 (en) 2013-03-22 2014-09-25 Millennium Pharmaceuticals, Inc. Combination of catalytic mtorc1/2 inhibitors and selective inhibitors of aurora a kinase
GB201321732D0 (en) * 2013-12-09 2014-01-22 Ucb Pharma Sa Therapeutic agents
CN111943962A (zh) 2015-02-27 2020-11-17 大鹏药品工业株式会社 咪唑并噁嗪晶体、含有所述晶体的药物组合物和制备所述晶体的方法
US11883404B2 (en) 2016-03-04 2024-01-30 Taiho Pharmaceuticals Co., Ltd. Preparation and composition for treatment of malignant tumors
WO2018081167A1 (en) * 2016-10-24 2018-05-03 Yumanity Therapeutics Compounds and uses thereof
CA3083000A1 (en) 2017-10-24 2019-05-02 Yumanity Therapeutics, Inc. Compounds and uses thereof
CA3127791A1 (en) 2019-01-24 2020-07-30 Yumanity Therapeutics, Inc. Compounds and uses thereof

Family Cites Families (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ATE361297T1 (de) * 2000-03-31 2007-05-15 Ortho Mcneil Pharm Inc Phenyl-substituierte imidazopyridine
ATE300540T1 (de) * 2000-04-27 2005-08-15 Yamanouchi Pharma Co Ltd Imidazopyridin-derivate
US7579355B2 (en) * 2003-04-24 2009-08-25 Merck & Co., Inc. Inhibitors of Akt activity
KR20060034303A (ko) * 2003-07-30 2006-04-21 라보라토리오스 에스.에이.엘.브이.에이.티., 에스.에이. 암을 예방하고 치료하기 위한 치환된 이미다조피리미딘
CA2561311A1 (en) 2004-04-09 2005-10-27 Merck & Co., Inc. Inhibitors of akt activity
US7544677B2 (en) 2004-08-23 2009-06-09 Merck & Co., Inc. Inhibitors of Akt activity
CN101242834A (zh) * 2004-12-15 2008-08-13 默克公司 Akt活性抑制剂
EP1902056A2 (de) 2005-05-20 2008-03-26 Array Biopharma, Inc. Raf-hemmende verbindungen und anwendungsverfahren dafür
WO2007025090A2 (en) 2005-08-25 2007-03-01 Kalypsys, Inc. Heterobicyclic and - tricyclic inhibitors of mapk/erk kinase
WO2007028051A2 (en) * 2005-09-02 2007-03-08 Abbott Laboratories Novel imidazo based heterocycles
PE20070978A1 (es) * 2006-02-14 2007-11-15 Novartis Ag COMPUESTOS HETEROCICLICOS COMO INHIBIDORES DE FOSFATIDILINOSITOL 3-QUINASAS (PI3Ks)
US7530313B2 (en) 2006-05-12 2009-05-12 Day & Zimmerman, Inc. Self-destruct fuze delay mechanism
US8592591B2 (en) * 2007-08-14 2013-11-26 Bayer Intellectual Property Gmbh Fused bicyclic imidazoles

Also Published As

Publication number Publication date
PA8793301A1 (es) 2009-04-23
TW200924761A (en) 2009-06-16
EP2176259B1 (de) 2011-03-30
EP2176259A1 (de) 2010-04-21
MX2010001745A (es) 2010-03-10
AU2008288390A1 (en) 2009-02-19
US20090156604A1 (en) 2009-06-18
CN101835776A (zh) 2010-09-15
KR20100049589A (ko) 2010-05-12
CA2695251C (en) 2016-06-21
US8592591B2 (en) 2013-11-26
CR11271A (es) 2010-05-19
US9387204B2 (en) 2016-07-12
US20140088110A1 (en) 2014-03-27
EA201000297A1 (ru) 2010-08-30
UY31292A1 (es) 2009-03-31
AR067946A1 (es) 2009-10-28
MA31609B1 (fr) 2010-08-02
SV2010003482A (es) 2010-07-06
TN2010000071A1 (en) 2011-09-26
ECSP109965A (es) 2010-03-31
PE20090596A1 (es) 2009-06-07
JP2010535847A (ja) 2010-11-25
CA2695251A1 (en) 2009-02-19
WO2009021990A1 (en) 2009-02-19
CL2008002397A1 (es) 2009-09-25
JP5327652B2 (ja) 2013-10-30
DE602008005894D1 (de) 2011-05-12
DOP2010000057A (es) 2010-04-15

Similar Documents

Publication Publication Date Title
ATE503757T1 (de) Kondensierte imidazole zur krebsbehandlung
BRPI0810206A2 (pt) Método de tratar câncer
IT1391555B1 (it) Apparato trattamento extracorporeo sangue
BR112012005594A2 (pt) tratamento de câncer
DK3289876T3 (da) Forbindelser til behandling af cancer
DK2121139T3 (da) Formulations for cancer treatment
ZA201003938B (en) Immersion treatment system
BRPI0817609A2 (pt) Derivados de imidazol
BRPI0912683A2 (pt) tratamento de tumores metastáticos
EP2357022A4 (de) Strahlungsbehandlungssystem
BRPI0922884A2 (pt) compostos para tratamento de câncer
BRPI0818855A2 (pt) Derivados de imidazol
BRPI0909016A2 (pt) anticorpos úteis para o tratamento do câncer
ATE446292T1 (de) Heterocyclylamid-substituierte imidazole
SE0702686L (sv) Förfarande för säkra transaktioner
HK1254607A1 (zh) 用於治療癌症的有機砷化合物
BRPI0918508A2 (pt) orto-aminoanilidas para o tratamento de câncer
BRPI0913872A2 (pt) multi-bandagem
BRPI0818863A2 (pt) Derivados de imidazol
BR112012003653A2 (pt) "método de tratar o câncer."
EP2281575A4 (de) Antikörper zur behandlung von krebs
GB0802201D0 (en) Treatment system
BRPI0916970A2 (pt) Combinações de imidazol substituído
GB0707556D0 (en) Treatment for cancer
BRPI0815772A2 (pt) Tratamento de câncer de pulmão

Legal Events

Date Code Title Description
RER Ceased as to paragraph 5 lit. 3 law introducing patent treaties